Link: Johnson & Johnson Unit Reveals Positive Data On Ceftobiprole.
Johnson & Johnson’s (JNJ) Pharmaceutical Research & Development unit said results from a Phase III trial showed that its investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections, including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA).
The company said the trial, which enrolled 257 patients, showed ceftobiprole was well tolerated in the treatment of complicated skin and skin structure infections, including diabetic foot infections.
